Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 37, 2002 - Issue 10
Submit an article Journal homepage
8
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Viral Kinetics and Treatment Response in Patients with Hepatitis C During Induction and Standard Interferon Therapy in Combination with Ribavirin

T. Carlsson
,
O. Weiland
&
O. Reichard
Pages 1228-1234 | Published online: 08 Jul 2009

  • Poynard T, Bedossa P, Oplon P, for the OBSTIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997:349:825-32.
  • Tong MJ, Neveen S, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion associated hepatitis C. N Engl J Med 1995:332:1463-6.
  • Reichard O, Norkrans G, FrydU+00E- A, Braconier J-H, Sönnerboo- A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon -2b with and without ribavirin for chronic hepatitis C. Lancet 1998:351:83-7.
  • McHutchison J, Gordon S, Schiff E, Shiffman M, Lee W, Rustgi V, et al. for the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as treatment for chronic hepatitis C. N Engl J Med 1998:339:1485-92.
  • Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. and the International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998:352:1426-32.
  • Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-- therapy. Science 1998+ADs-282: 103-7.
  • Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996:23:366-71.
  • Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interfereon alfa. Hepatology 1997+ADs-26:22631.
  • Neumann UA, Lam PN, Dahari H, Davidian M, Wiley ET, Mika PB, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000+ADs- 182:28-35.
  • Zeuzem S, Herrmann E, Lee JL, Fricke J, Neumann AU, Modi M, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterfero n alfa-2a. Gastroenterology 2001+ADs- 120:1438-47.
  • Carlsson T, Reichard O, Weiland O. Hepatitis C virus kinetics during induction and standard three times a week interferon alpha therapy. Scand J Infect Dis 2001+ADs-33:838-42.
  • Pawlotsky J-M, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000+ADs-32:654-59.
  • Doglio A, Laffont C, Caroli-Bosc FX, Rochet P, Lefebvre J. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 1999:37:1567-69.
  • Stuyver L, Wyseur A, Arnhem v W, Hemandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996:34:2259-66.
  • Yun ZB, Lara C, Johansson B, Lorenzana de Rivera I, Sönnerboo- A. Discrepancy hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol 1996:49:155-60.
  • Batts KP, Ludwig J. Chronic hepatitis. Am J Surg Pathol 1995:19:1409-17.
  • Schvarcz R, Glaumann H, Reichard O, Weiland O. Histological and virological long-term outcome in patients treated with interferon alfa-2b and ribavirin for chronic hepatitis C. J Viral Hepatol 1999:6:237-42.
  • Zeuzem S, Feinman V, Rasenack J, Heathcote J, Lai MY, Gane E, et al. Peginterfero n alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000:343:1666-72.
  • Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Schiffman M, Reindollar R, et al. Peginterfero n alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001:358:958-65.
  • Björg- K, Bell H, Helium KB, Skaug K, Raknerud N, Sandvei P, et al. Effect of combined interferon-alfa induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002:37:226-32.
  • Carithers RI Jr, Zeuzem S, Manns MP, McHutchison JG, Perillo RP, Bailey R, et al. Multicenter, randomized, controlled trial comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa-2b plus ribavirin. Hepatology 2000+ADs-32:317A.
  • Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001:34:1006-11.
  • Jessner W, Gschwantler M, Steindl-Munda P, Hofer H, WatkinsRiedel T, Wrba F, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001:358:1241-2.
  • National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology 1997+ADs-26 Suppl 1:2S-10S.
  • EASL International Consensus Conference on Hepatitis C. Consensus statement. J Hepatol 1999:30:956-61.
  • Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001:33:419-23.
  • Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998:28:245-52.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.